OR-AIRSHIP
12.10.2021 15:02:08 CEST | Business Wire | Press release
Customer engagement company Airship today announced the line-up for Elevate 2021 , the second annual global virtual forum for marketers and mobile product owners, taking place October 27-28, 2021. Experts in mobile app experience and engagement will share how they’ve adapted and accelerated strategies to capture more value from mobile and drive competitive differentiation. Confirmed speakers include executives from Ace Hardware, The Allstate Corporation, Chipotle, CNBC, DAZN, Douglas, Disneyland Paris, GetPlus, Hawaiian Airlines, KeyBank, EnBW, Kilo Health, Onefootball, Ryde Technologies, Shell, Sirius XM, Synchrony, Ulta Beauty and YTL Communications — with more to come.
Registration for Elevate 2021 is free, with many more reasons to attend , and programming begins October 27 at 9 a.m. PDT for the Americas. Programming for APAC and EMEA starts October 28 at 8 a.m. IST/12:30 p.m. AEDT and 1 p.m. BST, respectively. In addition to keynotes, customer-led sessions and panels, small group breakout sessions will enable peer-to-peer discussions and networking opportunities. Elevate 2021 is hosted in partnership with AppsFlyer, Mixpanel and mParticle.
Leading technology analyst and visionary Benedict Evans, formerly of Andreessen Horowitz (a16z), will deliver the first featured keynote providing a macro view of all the ways that brand, retail, e-commerce, advertising and marketing are being overturned, and how mobile apps are becoming the universal touchpoint, fueling new models of customer experience that require brands to adapt to changing consumer behaviors. Following that, Jonathan Kay, co-founder and CEO of Apptopia, will share comprehensive data and insights into consumer app trends and how brands are driving app-first initiatives across industry verticals.
“Today, mobile apps are becoming a definitive destination for consumers and brands. This growing shift requires a new way of thinking and operating in order for brands to create and capture new levels of value,” said Brett Caine, CEO and president, Airship. “Elevate 2021’s unique blend of live, interactive content and virtual breakout rooms led by the world’s foremost experts, offers the perfect place for marketers, mobile product owners, developers and others to gain inspiration and knowledge from those who are successfully responding to what this shift means for their customers and brands.”
Airship in Independent Industry Analyst Evaluations
Airship was recently named a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category and the second highest score in the Current Offering category.
Also, for the second consecutive year, Airship was positioned highest in its ability to execute and also furthest for its completeness of vision in Gartner’s 2020 Magic Quadrant for Mobile Marketing Platforms 1 , and received the highest Product Scores across all three Use Cases in Gartner’s 2020 Critical Capabilities for Mobile Marketing Platforms 2 , including the Acquisition, Engagement and Retention Use Cases.
1 Gartner “Magic Quadrant for Mobile Marketing Platforms ” by Mike McGuire, Anna Maria Virzi, Joseph Enever, October 26, 2020
2 Gartner “Critical Capabilities for Mobile Marketing Platforms ” by Mike McGuire, Anna Maria Virzi, Joseph Enever, October 29, 2020
Gartner Disclosure
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Airship
Thousands of the world’s leading brands rely on Airship to spark exceptional experiences with their customers through highly contextual and relevant interactions. Only Airship’s SaaS Customer Engagement Platform takes a mobile-first, data-led approach that enables brands to focus on individuals and their needs, rather than which marketing channels to use. Airship makes it much simpler and more effective to grow customer lifetime value in the omnichannel era.
With trillions of interactions intelligently orchestrated across mobile apps, mobile wallet, SMS, websites, and email, Airship optimizes the entire customer journey across all digital touchpoints at scale.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005465/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom